

Supplementary Table 4. Cox regression analysis of risk factors for HCC progression in patients with Vp1-3 (n = 62)

Variable	Univariate analyses			Multivariate analyses		
	HR	95% CI	<i>p</i> -value	aHR	95% CI	<i>p</i> -value
RT	0.60	0.32-1.15	0.13	0.29	0.13-0.62	0.002
Age (years)	0.98	0.95-1.01	0.17	-	-	-
Male	0.50	0.25-1.02	0.06	-	-	-
Presence of cirrhosis	0.82	0.44-1.53	0.54	-	-	-
HBsAg positivity	1.15	0.61-2.19	0.66	-	-	-
Anti-HCV positivity	0.79	0.24-2.58	0.70	-	-	-
Alcohol use disorder	0.99	0.45-2.15	0.98	-	-	-
ALT (U/L)	1.01	1.00-1.02	0.02	1.01	1.00-1.02	0.04
AST (U/L)	1.01	1.00-1.01	0.000	1.01	1.00-1.01	0.05
Bilirubin (mg/dL)	2.02	1.29-3.16	0.002	1.97	1.09-3.56	0.03
Albumin (g/dL)	0.55	0.30-1.01	0.05	-	-	-
PT (INR)	25.74	0.85-780.77	0.06	-	-	-
log _e AFP (ng/mL)	1.05	0.97-1.13	0.26	-	-	-
Tumor size > 10 cm	1.14	0.61-2.10	0.68	-	-	-
Multiple tumor nodules	1.32	0.68-2.57	0.42	-	-	-
Vp4	-	-	-	-	-	-
Hepatic vein invasion	3.07	1.06-8.88	0.04	1.69	0.49-5.87	0.41
Bile duct invasion	1.15	0.45-2.95	0.77	-	-	-
Distant metastasis	1.14	0.62-2.09	0.67	-	-	-
Previous locoregional therapy	0.74	0.40-1.38	0.34	-	-	-

HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; RT, radiation therapy; HBsAg, hepatitis B surface antibody; HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein.